Abstract
BackgroundSacituzumab govitecan (SG) demonstrated an ORR of 27% and median OS of 10.5 months (Mo) in metastatic urothelial carcinoma (mUC) patients (pts) progressing after platinum chemotherapy and PD1/L1 inhibitor. The...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
